Progenity Acquires Medimetrics Assets and Strengthens Global Leadership Position for Ingestible Device Technologies

“With the acquisition of Medimetrics’ assets, Progenity now holds one of the most robust ingestible device patent estates,” said Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity. “The synergy of Medimetrics’ technology with our own should allow us to greatly advance development and commercialization of our pipeline of ingestible technologies and therapeutics. Our aim is to improve understanding, diagnosis, and treatment of gastrointestinal diseases, ultimately enabling precision medicine.”

The agreement includes the purchase of Medimetrics’ patent portfolio for ingestible device technologies, which consists of 137 granted patents and 15 pending applications in the U.S., Europe, China, and Japan. Together with existing patents, Progenity’s ingestible device intellectual property portfolio now encompasses a broad range of technological advances. These include autonomous self-localization, sample collection and preservation from pre-selected GI locations, and targeted therapeutic delivery to the GI tract for topical and systemic applications. Progenity’s total patent portfolio now includes 200 granted patents and 216 pending applications across the company’s diagnostic and therapeutic platforms. Financial terms of the agreement were not disclosed.

“Medimetrics’ expertise in device development and system engineering set the stage for ingestible drug delivery and sampling, even garnering CE marks for several products for clinical and commercial use,” said Jeff Shimizu, director of device development at Progenity and former chief technology officer at Medimetrics. “We are continuing to demonstrate the potential of ingestible technologies to improve the overall standard of care for gastrointestinal health.”

Diagnosis and treatment of GI conditions such as small intestinal bacterial overgrowth (SIBO) and inflammatory bowel disease (IBD) remains difficult due to costly, invasive procedures and limited therapeutic options. As a result, millions of people with these conditions remain underserved. Progenity is developing ingestible technologies and therapeutics designed to diagnose and treat at the site of disease in the GI tract. Progenity’s systems have the potential to offer clinicians a noninvasive option for diagnosing, treating, and monitoring GI disease.

To learn more about Progenity’s precision medicine platforms, please visit www.progenity.com.

About Progenity

Progenity, Inc., is a privately held biotechnology company with the mission of transforming healthcare to be more precise and personal. The company is translating innovation into precision medicine through diagnostic and therapeutic development platforms based on genomics/epigenomics, proteomics, and microbiomics. These platforms feed an R&D pipeline of innovative products designed to improve patient outcomes in prenatal and perinatal healthcare settings, oncology, and gastroenterology. Progenity’s ultimate vision is to make precision medicine a reality by both diagnosing disease at its source and treating it with targeted therapies developed by the company. Progenity is headquartered in San Diego, California. For more information on how Progenity is helping clinicians and patients prepare for life, please visit https://www.progenity.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190918005119/en/